How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.
about
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
How can erythropoeitin-stimula ...... ism in chronic kidney disease.
@en
type
label
How can erythropoeitin-stimula ...... ism in chronic kidney disease.
@en
prefLabel
How can erythropoeitin-stimula ...... ism in chronic kidney disease.
@en
P2860
P356
P1433
P1476
How can erythropoeitin-stimula ...... dism in chronic kidney disease
@en
P2093
Christopher T Chan
P2860
P304
P356
10.1111/SDI.12106
P577
2013-06-05T00:00:00Z